SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del art韈ulo

LUQUE, M. et al. Estudio retrospectivo en pacientes con diagn贸stico de carcinoma de pulm贸n no microc铆tico estadio avanzado tratados con la combinaci贸n gemcitabina y vinorelbina: valoraci贸n de la eficacia terap茅utica y factores pron贸sticos. Oncolog铆a (Barc.) [online]. 2007, vol.30, n.2, pp.32-43. ISSN 0378-4835.

    1. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218 [ Links ]

    2. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291 [ Links ]

    3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98 [ Links ]

    4. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024 [ Links ]

    5. Smit EF, Van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21: 3909-3917 [ Links ]

    6. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 2001; 357: 1478-1484 [ Links ]

    7. Pujol JL, Breton JL, Gervais R et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16: 602-610 [ Links ]

    8. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advances non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585 [ Links ]

    9. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034 [ Links ]

    10. Alberola V, Camps C, Provencio M, et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213 [ Links ]

    11. Tan EH, Szczesna A, Krzakowski et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49: 233-240 [ Links ]

    12. Laack E, Dickgreber N, Muller T et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004; 22: 2348-2356 [ Links ]

    13. D'Addario G, Pintilie M, Leighl NB, Feld RD, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936 [ Links ]

    14. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of unresectable non-small cell lung cancer Guideline: Update 2003. J Clin Oncol 2004; 22(2): 330-353 [ Links ]

    15. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: An eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-709. [ Links ]

    16. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626 [ Links ]

    17. Paesmans M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analyses including recursive partotioning and amalgamation algorithms in 1,052 patients_The European Lung Canacer Working Party. J Clin Oncol 1995; 13: 1221-1230 [ Links ]

    18. Esteban E, Fra J, Corral N et al. Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs 2002; 20: 73-82 [ Links ]

    19. Esteban E, Fra J, Fernández Y et al. Gemcitabine and vinorelbine versus cisplatino, gemcitabine and vinorelbine as first-line treatment in advanced non-small cell lung cancer: Results of a prospective randomized phase II study. Invest New Drugs 2006; 24: 241-248 [ Links ]

    20. Fernández Y, Esteban E, Villanueva N et al. Prospective randomized phase II study of gemcitabine and vinorelbine versus gemcitabine and docetaxel combination in patients with previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2006; 24: Abstract 17052 [ Links ]

    21. Miller AB, Hooqstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214 [ Links ]

    22. Nie NH, Hull CH, Jenkins JG et al. Statistical Package for the Social Sciences. Chicago, IL SPSS Inc, 1988 [ Links ]

    23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481 [ Links ]

    24. Cox DR, Oakes D. Analysis of survival data. London, United Kingdom. Chapman & Hall, 1984 [ Links ]

    25. Brundage M, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-1057 [ Links ]

    26. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 2005; 23:175-183. [ Links ]

    27. Nordquist LT, Simon GR, Cantor A. Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung. Chest. 2004; 126:347-351 [ Links ]

    28. Chen YM, Perng RP, Yang KY et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000; 117: 1583-1589 [ Links ]

    29. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005; 28: 6865-6872 [ Links ]

    30. Gurubhagatula S, Liu G, Park S et al. XPD y XRCC1 genetic polymorphisms are prognostic factors in advanced non-small cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-2601 [ Links ]

    31. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expresión levels as an indicador of chemoresistance in lung cancer. Human Molecular Genetics 2004; 13: 2443-2449 [ Links ]

    32. Ramírez JL, Rosell R, Taron M et al. 14-3-3 _ methylation in pretreatment serum circulating DNA of Cisplatin-plus-gemcitabine-treated advanced non-small cell lung cancer patients predict survival: The Spanish Lung Cancer Group. J Clin Oncol 2005; 23:9105-9112 [ Links ]